Article

Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome

2018-03-13

Abstract excerpt

<h4>INTRODUCTION</h4> Down syndrome (DS) may be considered a genetic form of Alzheimer’s disease (AD) due to universal development of AD neuropathology, but diagnosis and treatment trials are hampered by a lack of reliable blood biomarkers. A potential biomarker is neurofilament light (NF-L), due to its association with axonal damage in neurodegenerative conditions. <h4>METHODS</h4> We measured blood NF-L concen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b961f203-095f-5417-ab29-8ed5a018de5b
DOI: 10.1101/281139

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neurofilament light as a blood biomarker for neurodegeneration in Down syndromeDOI 10.1101/281139Read

Neurofilament light as a blood biomarker for neurodegeneration in Down syndromeSemantic proximity Read

Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patientsSemantic proximity Read

Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) StudySemantic proximity Read

The Potential of Neurofilament Light as a Biomarker in Alzheimer’s DiseaseSemantic proximity Read

Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increaseSemantic proximity Read

Genome-wide Association Study Meta-analysis of Neurofilament light (NfL) levels in blood reveals novel loci related to neurodegenerationSemantic proximity Read

Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disordersSemantic proximity Read

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s diseaseSemantic proximity Read

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s diseaseSemantic proximity Read

Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disordersSemantic proximity Read

Aging with Down Syndrome—Where Are We Now and Where Are We Going?Semantic proximity Read

The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseasesSemantic proximity Read